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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare aspirin and other anti-inflammatory drugs with placebo in the treatment of Alzheimer's disease.
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B A C K G R O U N D
Alzheimer's disease (AD) is the most common form of dementia,
and its incidence increases exponentially with age, aHecting 1-2%
of 65 to 70 year olds and approximately 20% of those over 80 years
(Jorm 2003). It results in a progressive deterioration of intellect,
memory and personality. Evidence has accumulated to suggest
that altered production, aggregation and deposition of amyloid β
protein (Aβ) plays a critical role in the development of Alzheimer's
disease. Aβ is a proteolytic fragment of 40-42 residues derived
from Amyloid Precursor Protein (APP). In vitro, the longer Aβ-42
fragment aggregates much more readily, and is felt to be the main
culprit in the pathogenesis of AD. Genetic studies of patients with
early onset AD who have mutations in APP or presenilins show
selective increases in the relative levels of Aβ-42 peptides. This
leads to a series of reactions that result in neuronal dysfunction and
death. Activation of microglia and astrocytes results in a cascade
of inflammatory reactions with elevated levels of cytokines, acute-
phase proteins and complement proteins (Aisen 1994). These
substances are capable of reciprocally inducing each other and
enhancing neurotoxicity.
Attenuation of inflammatory processes can occur through
inhibition of the enzyme cyclo-oxygenase which is the mechanism
by which non-steroidal anti-inflammatory drugs (NSAIDs) function.
This prevents the production of prostaglandins which induce
cytokines. Corticosteroids cause alterations in inflammatory
responses through other mechanisms.
There is also evidence to suggest that some non-steroidal anti-
inflammatory drugs can directly influence the processing of APP
via direct modulation of the enzyme γ-secretase (Weggen 2003),
leading to alterations in the amount of Aβ- 42 produced (Eriksen
2003).
Evidence implicating inflammatory processes in AD also comes
from retrospective epidemiological studies. It has been observed
that patients who have received treatment with anti-inflammatory
drugs; e.g. patients with rheumatoid arthritis; have a lower
prevalence of AD (McGeer 1996). Prospective cohort studies have
also demonstrated a reduction in the relative risk of developing AD
in those taking non-steroidal anti-inflammatories compared with
non-users (Rich 1995); as well as a relationship with duration of use
(In't Veld 2001).
There has been no meta-analysis of the eHicacy of anti-
inflammatory drugs as a class in the treatment of Alzheimer's
disease, although some of the drugs have previously been reviewed
individually by the Cochrane Collaboration (Tabet 2002; Tabet
2003). This analysis will therefore build on previous reviews. The
authors also propose to conduct a subgroup analysis looking
at drugs that have allosteric modulating properties, as it is
hypothesised that subtle diHerences in their mechanism of action
may explain the variability in trial results reported to date.
O B J E C T I V E S
To compare aspirin and other anti-inflammatory drugs with
placebo in the treatment of Alzheimer's disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised double-blind placebo-controlled trials assessing
the eHicacy of aspirin and other anti-inflammatory drugs in the
treatment of Alzheimer's disease.
Types of participants
Patients of any age diagnosed with probable Alzheimer's according
to internationally recognised criteria such as *NINCDS-ADRDA, DSM
and ICD (McKhann 1984; APA 1995; WHO 1992) will be eligible for
inclusion. Patients should not have extensive prior use of these
medications.
*NINCDS-ADRDA refers to the 'National Institute of Neurologic and
Communicative Disorders and Stroke and the Alzheimer's Disease
and Related Disorders Association'. DSM refers to the 'Diagnostic
and Statistical Manual of Mental Disorders'. ICD-10 refers to
World Health Organisation classification of mental and behavioural
disorders, the clinical description and diagnostic guidelines.
Types of interventions
Comparisons of aspirin and all other anti-inflammatory drugs at
any dose with placebo.
Types of outcome measures
• Cognition (using objective psychometric rating instruments e.g.
the Alzheimer's disease assessment scale - cognitive subscale or
ADAS-COG)
• Clinical global impression of change
• Mood/depression
• Behavioural disturbance
• Activities of daily living




Search methods for identification of studies
The trials will be identified from a search of the Specialized
Register of the Cochrane Dementia and Cognitive Improvement
Group using the following terms: aspirin, aceclofenac, acemetacin,
betamethasone, celecoxib, cortisone, deflazacort, dexamethasone,
dexibruprofen, dexketoprofen, diclofenac sodium, diflusinal,
etodolac, etoricoxib, fenbufen, fenoprofen, flurbiprofen,
hydrocortisone, ibuprofen, indometacin, ketoprofen, lumiracoxib,
mefenamic acid, meloxicam, methylprednisolone, nabumetone,
naproxen, nimesulide, piroxicam, sulindac, tenoxicam, tiaprofenic
acid and triamcinolone.
This Register contains records from all major healthcare databases
and many ongoing trial databases and is updated regularly.
Aspirin and anti-inflammatory drugs for Alzheimer's disease (Protocol)
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Data collection and analysis
Selection of studies
Three reviewers (RQ, MI, NT) will independently examine the titles
and abstracts of the trials identified in the search and will consider
them for inclusion according to the pre-determined eligibility
criteria. Any disparity will be resolved by retrieval of the cited
articles and further discussion.
Quality assessment
The quality of the methods used in each study will be examined by
the three reviewers using one of the Cochrane approaches:
Grade A: Adequate concealment (randomization; placebo-
controlled; concealed allocation).
Grade B: Uncertain.
Grade C: Inadequate concealment; no randomization.
The rating of quality will be described in the table of included
studies.
Data extraction
Data will be extracted using a data collection form by two of
the authors (RQ, MI), and any disagreements will be resolved by
discussion.
'Intention to treat analysis' will be applied to data obtained on
every randomized patient.
For continuous variables, or ordinal variables approximated to
continuous variables, outcomes of interest will be the assessment
score at the time point considered, and the change from baseline.
For some binary outcomes the end point itself will be of clinical
relevance. In other cases it may be necessary, due to variation
in the way response to treatment is measured, to operationalize
outcomes as 'improved' versus 'not improved' regardless of the
scales used by the authors.
Data analysis
Missing data and drop out rates will be assessed for each of the
included studies. The number of participants who are included in
the final analysis will be reported as a proportion of all participants
in the study.
For binary outcomes a standard estimation of the odds ratio and
risk ratio with a 95% confidence interval will be calculated.
Continuous data with a normal distribution will be analysed by
Review Manager soPware if means and standard deviations are
available, to obtain a standardised diHerence in means (SMD).
Appropriate non-parametric tests will be used to analyse data that
is not normally distributed.
If there are suHicient data, and it is appropriate to do so (aPer
assessing heterogeneity visually, and utilizing a Chi-squared test),
a meta-analysis will be conducted. A subgroup analysis of those
drugs with allosteric modulating properties is also planned.
A C K N O W L E D G E M E N T S
The authors wish to thank the consumer editor, Lynne Ramsay, for
her helpful comments.
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W H A T ' S   N E W
 
Date Event Description
26 August 2008 Amended When the full review of "Aspirin and anti-inflammatory drugs for
Alzheimer's disease" is published, it will replace the previous-
ly published reviews "Ibuprofen for Alzheimer's Disease", "In-
domethacin for Alzheimer's Disease", and the previously pub-
lished protocol "Naproxen for Alzheimer's Disease". 
 
At that time, these ibuprofen and indomethacin reviews and this
naproxen protocol will be withdrawn from the Cochrane Library.
26 August 2008 Amended Converted to new review format.
 
C O N T R I B U T I O N S   O F   A U T H O R S
RQ: Writing & coordinating the review, searching & selecting trials for inclusion, extracting & interpreting data, and entering data on to
Revman.
MI and NT will contribute to the searching for trials, obtaining copies of trial reports and to selecting trials for inclusion/exclusion. They
will also be involved in data extraction and interpretation, and providing general advice on the review.
Contact editors: Leon Flicker and Gordon Wilcock
Consumer editor: Lynne Ramsay
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D E C L A R A T I O N S   O F   I N T E R E S T
None known.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Alzheimer Disease  [*drug therapy]  [etiology];  Anti-Inflammatory Agents  [adverse eHects]  [*therapeutic use];  Anti-Inflammatory
Agents, Non-Steroidal  [adverse eHects]  [*therapeutic use];  Aspirin  [adverse eHects]  [*therapeutic use];  Cyclooxygenase 2 Inhibitors
 [adverse eHects]  [therapeutic use];  Glucocorticoids  [adverse eHects]  [therapeutic use];  Inflammation  [complications]  [drug therapy]; 
Randomized Controlled Trials as Topic;  Treatment Outcome
MeSH check words
Aged; Aged, 80 and over; Humans
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